Clinical Trial

Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This phase I trial studies the side effects and best dose of pacritinib when given together with venetoclax and azacitidine in treating patients with accelerated and blast phase myeloproliferative neoplasms (MPN-AP/BP). Pacritinib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving pacritinib together with venetoclax and azacitidine may be safe, tolerable, and/or effective in treating patients with MPN-AP/BP
Protocol Amendment History 2 changes
notable Primary completion pushed: 2028-08-01 -> 2028-09-01 2026-08-01
minor Completion pushed: 2029-08-01 -> 2029-09-01 2026-08-01
Trial Details
NCT Number NCT07679334
Lead Sponsor Roswell Park Cancer Institute
Conditions Myeloproliferative Neoplasm
Enrollment 20 participants
Start Date 2026-09-01
Primary Completion 2028-09-01 (estimated)
Study Completion 2029-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-31